Why This Gene-Editing Stock Is Soaring — Live Feedhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaringContinuously updated, source-cited coverage. Intellia Stock Climbs on Lonvo-z Phase 3 Data; Gene-Editing Sector Eyes Momentumhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaringhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaring#u1204Tue, 16 Jun 2026 12:52:03 +0000Intellia Therapeutics shares rose after new Phase 3 results for its CRISPR-based therapy *Lonvo-z* showed significant reductions in hereditary angioedema (HAE) attacks, reinforcing its regulatory path. The FDA rolling submission for approval signals a potential market breakthrough, though execution risks remain. Analysts and investors are watching as gene-editing stocks maintain strong gains ahead of Q3 earnings. Cathie Wood’s Ark Invest continues to back Intellia as a high-conviction pick in the sector.What's confirmed:Intellia Therapeutics shares surged Monday following Phase 3 results for * Intellia stock jumps after Phase 3 CRISPR therapy data for hereditary angioedemahttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaringhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaring#u820Tue, 16 Jun 2026 06:11:47 +0000Intellia Therapeutics' shares rose Monday following positive Phase 3 results for its CRISPR-based treatment *Lonvo-z*, which targets hereditary angioedema (HAE). The therapy showed meaningful reductions in swelling attacks, fueling investor optimism despite prior mixed reactions to similar data. Analysts are now assessing the clinical impact against execution risks. The move highlights growing confidence in gene-editing therapies for rare diseases.What's confirmed:Intellia Therapeutics' stock surged Monday following promising Phase 3 results for its CRISPR-based treatment targeting h Intellia Stock Surges on CRISPR HAE Treatment Breakthroughhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaringhttps://www.live-feeds.com/feed/why-this-gene-editing-stock-is-soaring#u536Tue, 16 Jun 2026 01:31:31 +0000Intellia Therapeutics' stock is rising after announcing positive Phase 3 results for its one-time CRISPR-based treatment for hereditary angioedema (HAE). The therapy, *Lonvo-z*, demonstrated significant reductions in attacks, marking a potential paradigm shift for HAE patients. Shares jumped premarket, though prior reports noted mixed market reactions to similar data. Analysts and investors are weighing the clinical impact against execution risks.What's confirmed:Intellia Therapeutics reported Phase 3 results for *Lonvo-z*, its CRISPR-based therapy for hereditary angioedema, showing a sig